In a report published Wednesday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating on Boston Scientific Corporation BSX, and raised the price target from $17.00 to $20.00.
In the report, Morgan Stanley noted, "Strong YTD performance should not distract from Boston's long term restructuring story, which still has years to go. We expect the May analyst day to shed light on durable growth and margins that can extend beyond the 25% 2017 target. We remain Overweight and raise our price target to $20."
Boston Scientific closed on Tuesday at $17.40.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in